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1. Introduction
  Diabetes mellitus (DM) is a common endocrine disorder 
caused by an absolute or relative lack of insulin and/or 
reduced insulin activity that results in hyperglycemia and 
abnormalities in carbohydrate, fat and protein metabolism. 
The severity of diabetes is increasing day by day; the main 
cause of this problem is aging, urbanization and increasing 
privilege leading to obesity and physical inactivity. Now 
and in the future, it is important to quantify the prevalence 
of diabetes and to plan the allocation of resources towards 
treatment and prevention of this disease[1,2]. Management 
of diabetes without any side effects is still a challenge for 
medical system. This has leads researchers to search for 
antidiabetic drugs from plants used in traditional system 
of medicine. Recent studies have demonstrated that 
absorption inhibitors have a role in the prevention of type 2 
diabetes in high-risk populations[3]. Inhibitors of intestinal 
毩-glucosidase enzymes retard the rate of carbohydrate 
digestion, thereby providing an alternative means to reduce 
postprandial hyperglycemia[4].
  A plenty of traditional herbal medicinal practices have 
been adopted for the diagnosis, prevention and treatment of 
diabetes. The Ocimum sanctum (O. sanctum) belonging to 
family Lamiaceae is medicinally used in diabetes, digestive, 
diuretic, cardiopathy, haemopathy, leucoderma, asthma, 
bronchitis, catarrhal fever, otalgia, hepatopathy, lumbago, 
ophthalmia, gastropathy in children, GIT disorders, 
ringworm, verminosis and skin disease[5-10]. O. sanctum also 
showed antioxidant, lipid-lowering[11], anti-metastatic[12], 
antifungal[13], antibacterial[14], antimicrobial[15] and wound 
healing[16] activities.
  In an earlier study[17] view of traditional medicinal use, 
earlier we found that hydro alcoholic and chloroform 
extracts of O. sanctum aerial part were found to be effective 
in treating diabetes. The hydro alcoholic extract was 
found to be more potent than the chloroform extract. In 
view of this, the present study was undertaken to perform 
bioactivity guided fractionation for antidiabetic property of 
hydro alcoholic extracts of O. sanctum aerial part. 
Objective: To isolate and characterize antidiabetic component (bioactivity-guided fractionation) 
from hydro alcoholic extract of Ocimum sanctum (O. sanctum) aerial part. Methods: Ten 
fractions (F1 - F10) were isolated from hydro alcoholic extract of O. sanctum aerial part by column 
chromatography. All the fractions F1 to F10 were screened for antidiabetic activity in alloxan 
induced diabetic rats by estimating serum glucose level and lipid parameters. The isolated 
bioactive component was elucidated on the basis of extensive spectroscopic (UV, IR, MS, 1H and 
13C NMR) data analysis. Results: The bioactive fraction (F5) was found to be potent antidiabetic by 
ameliorating glucose and lipid parameters (total cholesterol, triglycerides, low and high density 
lipoprotein cholesterol). The extensive spectroscopic data analysis reveals that, the isolated 
bioactive compound elucidated as tetracyclic triterpenoid [16-Hydroxy-4,4,10,13-tetramethyl-
17-(4-methyl-pentyl)-hexadecahydro-cyclopenta[a]phenanthren-3-one]. Conclusions: Our 
present study concluded that, tetracyclic triterpenoid isolated from aerial part of O. sanctum has 
a great anti-diabetic potential.
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2. Materials and methods
2.1. Plant material
  The aerial part of O. sanctum Family Lamiaceae was 
collected from Pune district, Maharashtra, India in 
August, 2008 and authenticated by the Head of the Botany 
Department, Sharadabai Pawar College, Malegaon, 
Baramati taluka, Pune district, India. Voucher specimens 
were deposited in a herbarium of same institute for future 
reference. The aerial part was dried in a shade, and stored 
in the dark until use.
2.2. Chemicals and drugs
  Alloxan monohydrate, tolbutamide, methanol and 
chloroform were purchased from Sigma Chemicals (St. Louis, 
MO USA). Chemical kits for estimation of blood glucose, total 
cholesterol, triglycerides, low density lipoprotein (LDL) and 
high density lipoprotein (HDL) were purchased from Erba 
Diagnostics (Mannheim, Germany). All the other chemicals 
used were also of analytical grade.
2.3. Preparation of extract and fractionations
  Dried coarse powder of O. sanctum aerial part was 
extracted with a 4:6 (v/v) mixture of water and 95% ethanol 
by Soxhlet extraction at a 70 曟 temperature. The solvent 
was evaporated by a rotary evaporator and dried over a water 
bath at a 45 曟 temperature to yield the hydro alcoholic 
extract of O. sanctum (OSH). Dried extract OSH weighed in 
an analytical balance and stored at 5 曟 until use. The OSH 
sample was further fractionated by column chromatography 
(50 cm × 5 cm)  on silica gel (Mesh 60-120, Merck, 
Germany) eluting 100 mL each of methanol: chloroform 
mixture in ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2 and 9:1.
2.4. Animals
  The male albino rats (Wistar strain weighing 150-180 g) 
were procured from Shivnagar Vidya Prasarak Mandal’s 
College of Pharmacy, Malegaon, Baramati taluka, Pune 
district, India and were housed vivarium. The rasty were 
kept at (27依3) 曟 with relative humidity of (65依10)% and a 12 h
light/dark cycle. All animals were fed a rodent pellet diet 
(Gold Mohr, Lipton India Ltd.) and water was allowed ad 
libitum under strict hygienic conditions. The Institutional 
Animal Ethics Committee (IAEC) approved all the protocols 
of study (Reg. No. 1214/ac/08/CPCSEA).
2.5. Induction of diabetes
  The rats were intrapertoneally injected with alloxan 
monohydrate dissolved in normal saline at a dose of 150 mg/kg. 
After 2 weeks rats with serum blood glucose levels higher 
than 260 mg/dL were selected for the experiment[18].
2.6. Experimental design for anti-diabetic activity
  The rats were divided into 13 groups (n=6). Group I 
(the control group) received 0.5 mL saline, group II were 
untreated diabetic rats and group III were diabetic rats 
treated with 80 mg/kg tolbutamide. Groups IV to XIII 
included diabetic rats treated with fractions 1 to 10 (i.e. F1-
F12) of the OSH at a dosage of 20 mg/kg. Tolbutamide was 
used as the standard antidiabetic treatment throughout the 
experiment. The animals were carefully monitored on each 
day of the study. Animals described as fasted were deprived 
of food for at least 12 h but were allowed free access to 
drinking water. Fasting blood glucose measurements 
were performed on days 0, 7 and 14 of the study. Blood 
samples were collected using the retro orbital method at 
weekly intervals until the end of study and were processed 
for estimation of serum glucose by the glucose oxidase-
peroxidise (GOD-POD) method[19-21].
2.7. Estimation of lipid profile
  Serum samples from all the experimental rats were 
collected for the estimation of lipid parameters, total 
cholesterol by the oxidase-p-aminophenazone (CHOD-PAP) 
method, triglycerides by the glycerol phosphate oxidase 
(GPO) Triender method, high density lipoprotein (HDL) 
cholesterol and low density lipoprotein (LDL) cholesterol[22].
2.8. Characterization of bioactive fraction
  We carried out elemental analysis and detection of the 
melting point of the bioactive component identified in OSH. 
UV spectra were measured in methanol on a Shimadzu 
double beam 210A spectrophotometer. IR spectra were 
recorded with a Shimadzu FTIR-8400S spectrometer with 
the compound prepared as KBr pellets. 1H and 13C NMR 
spectra were recorded with a Bruker DRX-500 instrument 
using tetramethylsaline (TMS) as an internal standard. Mass 
spectral data were obtained with a Shimadzu MS QP 5000 
mass spectrometer. The melting point was obtained using a 
REMI-digital melting point apparatus.
2.9. Statistical analysis
  Data were expressed as the mean依SEM for all experiments. 
Significant differences between groups were calculated 
according to one-way analysis (ANOVA) followed by Tukey’s 
multiple comparison tests. Values corresponding to P<0.001 
were considered statistically significant.
3. Results
3.1. Bioactivity guided fractionation antidiabetic activity
  The yield of hydro alcoholic extract was 12.08% w/w.  The 
crude OSH was fractionated by column chromatography. The 
fractions were combined on the basis of their TLC pattern to 
afford 11 fractions viz. F1-5.01% w/w, F2-4.11% w/w, F3- 
5.43% w/w, F4-4.23% w/w, F5-6.71% w/w, F6-5.62% w/
w, F7-4.37% w/w, F8-5.14% w/w, F9-5.51% w/w and F10- 
4.81% w/w.
  It was intended to assess the fractionated components 
treatment on diabetes and associated abnormal lipid profile 
in alloxan-induced severely-diabetic rats. Rats were treated 
with all 10 fractions at a dose of 20 mg/kg and tolbutamide. 
Blood glucose and lipid profile parameter measurements 
were performed on days 0, 7 and 14. It was observed that, 
fractions F1, F2, F8 F9 & F10 demonstrated no antidiabetic 
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property. The fraction F5 was found to be strongest 
antidiabetic component, significantly (P<0.001) decreases 
the serum glucose level, total cholesterol, triglycerides and 
HDL cholesterol and increases serum LDL cholesterol level 
relative to untreated diabetic rats (Figure 1-4).
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Figure 1. Effect of fractions of OSH on serum glucose in diabetic rats 
on day 0.
*P<0.05 and *** P<0.001 when compare to untreated diabetic group.
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Figure 2. Effect of fractions of OSH on serum glucose in diabetic rats 
on day 7.
*P<0.05, **P<0.01 and ***P<0.001 when compare to untreated 
diabetic group.
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Figure 3. Effect of fractions of OSH on serum glucose in diabetic rats 
on day 14.
*P<0.05, **P<0.01 and ***P<0.001 when compare to untreated 
diabetic group.
3.2. Characterization of bioactive fraction (F5)
  The bioactive fraction (F5) was found to contain a 
compound which crystallized as colorless crystals with m.p. 
247-249 曟. The percentage of elements were present in 
bioactive fraction: C - 80.59%, H -11.44%, O - 7.96%; UV-Vis 
毸max  in  Methanol (nm): 206;  Rf: 0.41; IR 氃max (KBr) cm
-1: 
3465 (free OH), 3005 (C-H aromatic), 2930 (C-H aliphatic), 
1715 (C=O); MS: Molecular ion (M+) m/z 402;  1H NMR(200 
MHz, CDCl3): δ 0.76 (s, 
3H), 0.79 (q,1H, J = 11.0, J = 10.5, J = 
1.35), 0.83 (s, 3H), 0.87 (s, 6H), 1.01 (q, 2H, J = 11.0,4.50,3.0), 1.02 
(s,  3H), 1.07 (s, 3H), 1.07 (q, 1H, J = 8.12, J = 7.96, J = 5.0), 1.15 (t, 
2H, J = 13.10, J = 6.76), 1.17 (q, 2H, J = 12.8, J = 7.8, J = 7.20), 1.38 
(q, 2H, J = 13.59, J = 12.50, J = 2.03, 1.22 (q, 1H, J = 12.50, J = 4.47, 
J = 2.03), 1.27 (q, 2H, J = 11.40, J = 11.0, J = 6.76), 1.31 (p, 2H, J = 
7.80, J = 7.80, J = 7.78, J = 6.0), 1.33 (p, 2H, J = 11.0, J = 10.50, J 
= 5.0, J = 3.9), 1.43 (t, 1H, J = 11.0, J = 2.58), 1.44 (t, 2H, J = 13.5, 
J = 11.5, J = 6.0), 1.49 (t, 2H, J = 13.2, J = 8.12, J = 7.96), 1.50 (h, 
1H, J = 7.20, J = 6.47, J = 7.20, J = -0.47), 1.61 (q, 2H, J = 11.40, J 
= 11.0, J = 4.50), 2.38 (t, 2H, J = 11.50, J = 6.0, J = 5.0), 3.57 (s, 1H), 
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Figure 4. Effect of fractions of OSH on lipid parameters in diabetic rats.
 *P<0.05, **P<0.01 and ***P<0.001 when compare to untreated diabetic group.
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4.30 (q, 1H, J = 13.20, J = 8.12, J = 7.96); 13C NMR (125 Hz, CDCl3): 
δ 14.05 (CH3- 21), 15.25 (CH3- 22), 21.02 (C- 14), 21.32 (CH3- 
19), 22.62 (CH3- 27), 22.62 (CH3- 28), 24.27 (C- 24), 24.64 (C- 8), 
27.01 (C- 18), 28.57 (C- 26), 30.57 (C- 7), 34.45 (C- 5), 34.84 (C- 
23), 35.46 (C- 9), 36.32 (C- 17), 36.35 (C- 1), 38.11 (C- 3), 39.09 
(C- 25), 39.93 (C- 13), 42.44 (C- 11), 47.23 (C- 4), 51.21 (C- 10), 
53.56 (C- 2), 55.02 (C- 12), 59.33 (C- 15), 73.43 (C- 16), 217.49 
(C- 6).
  Based on the available spectroscopic data, it was 
concluded that, the bioactive component isolated from OSH 
was the triterpenoid [16-Hydroxy-4,4,10,13-tetramethyl-
17-(4-methyl-pentyl)-hexadecahydro-cyclopenta[a]
phenanthren-3-one], molecular formula: C27H46O2  and 
molecular weight: 402. The structure of the triterpenoid is 
depicted in Figure 5.
CH3
CH3
CH3
OH
H3C
H3C
H3C
O
Figure 5. Structure of triterpenoid.
4. Discussion
  Diabetes is a chronic metabolic disorder affecting 
significant portion of the global population. A sustained 
reduction in hyperglycaemia will decrease the risk of 
developing microvascular diseases and reduce their 
complications[23]. The conventional therapies for diabetes 
have many shortcomings in terms of side effects and high 
rates of secondary failure. On the other hand, herbal extracts 
are expected to have similar efficacies without the side 
effects of conventional drugs[24].
  Alloxan first identified as a pyrimidine derivative in 
1838, is one of the most prominent diabetogenic chemicals 
in diabetes research[25,26]. Alloxan induces diabetes in 
animals[27], as a result of specific necrosis of pancreatic 
毬 cells[28,29]. The resulting insulinopenia causes a state of 
experimental diabetes mellitus which is known as alloxan 
diabetes[30,31]. Alloxan is capable of generating reactive 
oxygen species (ROS) in a cyclic reaction with its reduction 
product, dialuric acid[32-35].
  O. sanctum is one of the most popular botanicals for the 
treatment of diabetes. It was reported that the triterpenoid 
with hydroxyl or carboxylic or ketonic groups possess 
significant anti-diabetic property. The 3-carboxylic acid or 
hydroxyl or ketonic substituted triterpenoid exhibits more 
significance than other triterpenoid[36-41].
  The present investigation reports the antidiabetogenic and 
hypoglycaemic property of triterpenoid. The antidiabetic 
and hypoglycemic potential of triterpenoid (F5) in alloxan 
diabetic rats may be due to, (a) potentiation of the insulin 
effect of plasma by increasing the pancreatic secretion of 
insulin from existing 毬 cells of islets of Langerhans or its 
release from bound insulin, and/or (b) enhanced glucose 
utilization by peripheral tissues. In this context a number 
of other plants have been observed to have similar type of 
hypoglycemic effect[42,43].
  The administration of triterpenoid (F5) significantly reduces 
the level of serum glucose, triglycerides, LDL cholesterol 
and total cholesterol in diabetic rats. A significant elevation 
of HDL cholesterol levels was also observed. These results, 
together with previous reports of triterpenoid having 
antidiabetic properties, suggest that triterpenoid have the 
potential to be developed as antidiabetic compounds.
  It is evident from the present work that, tetracyclic 
triterpenoid  isolated from aerial part of O. sanctum has 
a potential anti-diabetic as well as anti-hyperlipidemic 
effect, which is bioactivity of great relevance to diabetes 
mellitus complication therapy.
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